Stock Market Reviews

NRXS (NeurAxis, Inc.) News

Get the latest news, insights, and market updates on NRXS (NeurAxis, Inc.). Explore the news page 3 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• NeurAxis Announces Closing of $5.0 Million Registered Direct Offering
  Strengthens Balance Sheet and Provides Growth CapitalCARMEL, Ind., May 22, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, today announced the closing of its previously announced registered direct offering of 1,538,461 shares of its common stock at a purchase price of $3.25 per share. The gross proceeds from th
  May 22, 2025 - $NRXS
• NeurAxis Announces $5.0 Million Registered Direct Offering
  CARMEL, Ind., May 21, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 1,538,461 shares of its common stock at a purchase price of $3.25 per share in a registered direct offering priced at the market under
  May 21, 2025 - $NRXS
• NeurAxis Awarded First Ever FDA Clearance for the Treatment of Pediatric FAP/Functional Dyspepsia (FD) and Associated Nausea Symptoms
  • Significantly expands IB-Stim’s total addressable market • Clearance covers patients aged 8–21 • Seamless go-to-market strategy with existing reimbursement and provider infrastructure CARMEL, Ind., May 20, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, today announced that it has received FDA 510(k) clearanc
  May 20, 2025 - $NRXS
• NeurAxis Stock Gains Following Strong Q1 Earnings and FDA Milestones
  NRXS posts strong first-quarter 2025 earnings with robust revenue growth and FDA milestones, driving stock gains as investors eye broader insurance coverage and market expansion.
  May 15, 2025 - $NRXS
• NeurAxis Reports Strong First Quarter 2025 Financial Results Driven by a 39% Growth in Revenues
  Conference call will be held today, Monday, May 12 at 9:00 am ETCARMEL, Ind., May 12, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced results for the first quarter 2025 for the period ended March 31, 2025. 1Q25 Financial highlights Revenues increased 39% year over year to $896 thousand in 1Q25 compared
  May 12, 2025 - $NRXS